Texas Valley Clinical Research
Welcome,         Profile    Billing    Logout  
 13 Trials 
80 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Robertson, David
NCT06366464: A Study of Pitolisant in Patients with Prader-Willi Syndrome

Recruiting
3
134
US
Pitolisant tablet, pitolisant, Placebo tablet, placebo
Harmony Biosciences, LLC
Prader-Willi Syndrome
07/26
07/27
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

Recruiting
2
230
US
HDV-Lispro, HDV-L, Lispro, LIS
Diasome Pharmaceuticlas, Inc.
Diabetes Mellitus, Type 1
06/25
12/25
Hannon, Tamara
SURMOUNT-ADOLESCENTS-2, NCT06439277: A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities

Recruiting
3
300
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Weight Gain
05/27
06/27
SURPASS-PEDS, NCT05260021 / 2021-003612-31: A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

Active, not recruiting
3
99
Europe, US, RoW
Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
Eli Lilly and Company, Eli Lilly and Company
Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
07/24
02/25
NCT05577169: Incorporating Mind-body Skills with Diabetes Education in Adolescents with Type 1 Diabetes

Active, not recruiting
N/A
30
US
Mind-body skills, Diabetes education
Indiana University, Eli Lilly and Company
Type 1 Diabetes, Adolescent Behavior
12/24
12/24
Eder, Frank
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Recruiting
4
8600
US
Naltrexone-Bupropion (NB) Combination, Placebo
Currax Pharmaceuticals
Obesity
01/29
07/29
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4223
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
NCT06015282: The Celljuvant Study: a Phase 3 Immunogenicity and Safety Study of AQIVc Vaccine in Adults Aged 50 Years and Older

Active, not recruiting
3
7741
Europe, Canada, US, RoW
Investigational aQIVc, licensed QIV1, licensed QIV2
Seqirus
Influenza, Human
03/24
01/25
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
NCT05925127: Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines

Completed
2/3
994
US
NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), Omicron XBB.1.5, NVX-CoV2601(5μg), NVX-CoV2601 (35μg), NVX-CoV2601(35μg), NVX-CoV2601(50μg), Bivalent BA.4/5, Omicron Subvariant/Prototype Licensed mRNA Vaccine
Novavax
COVID-19
05/24
05/24
NCT04909021: Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Recruiting
1c
63
US
Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose), Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose), Placebo (single-dose), Placebo (two-dose)
Meissa Vaccines, Inc.
Respiratory Syncytial Virus (RSV)
10/23
10/23
NCT05477186: Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

Completed
1
180
US, RoW
CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg), CV0501 (25 μg), CV0501 (50 μg), CV0501 (75 μg), CV0501 (100 μg), CV0501 (150 μg), CV0501 (200 μg)
GlaxoSmithKline
COVID-19, SARS-CoV-2
08/23
08/23
Phan, Han
RESPOND, NCT04488133 / 2020-003492-18: A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec

Active, not recruiting
4
46
Europe, US, RoW
Nusinersen, ISIS 396443, BIIB058, Spinraza
Biogen
Muscular Atrophy, Spinal
10/25
10/25
RECONNECT, NCT04977986 / 2021-002542-33: Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults with Fragile X Syndrome

Recruiting
3
250
Europe, US, RoW
ZYN002 - transdermal gel, cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery), Placebo, Placebo Comparator, Matching Placebo
Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc.
Fragile X Syndrome
05/25
05/25
NCT06366464: A Study of Pitolisant in Patients with Prader-Willi Syndrome

Recruiting
3
134
US
Pitolisant tablet, pitolisant, Placebo tablet, placebo
Harmony Biosciences, LLC
Prader-Willi Syndrome
07/26
07/27
EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Recruiting
3
150
Europe, Canada, US, RoW
Ecopipam, Ecopipam Hydrochloride
Emalex Biosciences Inc.
Tourette Syndrome
11/24
03/27
MIS51ON, NCT03992430 / 2018-001762-42: A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD)

Active, not recruiting
3
160
Europe, US, RoW
Eteplirsen, AVI-4658, EXONDYS 51, EXONDYS
Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc.
Muscular Dystrophy, Duchenne
10/26
10/26
HOPE-3, NCT05126758: A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Recruiting
3
102
US
CAP-1002, Cardiosphere-Derived Cells (CDCs), Placebo
Capricor Inc.
Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases
12/24
12/26
D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Active, not recruiting
3
196
Europe, Canada, US, RoW
Ecopipam Hydrochloride
Emalex Biosciences Inc.
Tourette Disorder
12/24
12/24
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting
3
300
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Chronic Migraine
07/25
03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
ASCEND, NCT05067790 / 2021-001294-23: A Study to Evaluate Higher Dose (HD) Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Previously Treated With Risdiplam

Recruiting
3
45
Europe, Japan, US
Nusinersen, BIIB058, Spinraza
Biogen
Spinal Muscular Atrophy
06/27
06/27
Fortify, NCT05775848: Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Active, not recruiting
3
81
Europe, US, RoW
BBP-418 (ribitol), Placebo
ML Bio Solutions, Inc.
Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
07/27
07/27
NCT04336826 / 2020-000980-21: A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Completed
2
6
US
Ataluren, PTC124
PTC Therapeutics
Nonsene Mutation Duchenne Muscular Dystrophy
08/23
08/23
NCT04886518: Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

Hourglass Jul 2022 - Dec 2022 : Efficacy and safety data for treatment of EDS in patients with Myotonic Dystrophy Type 1
Active, not recruiting
2
30
Canada, US
Pitolisant Oral Tablet, Placebo oral tablet
Harmony Biosciences, LLC
Myotonic Dystrophy 1, Excessive Daytime Sleepiness
10/23
10/24
MOMENTUM, NCT04004065 / 2019-000601-77: Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

Checkmark From MOMENTUM trial for DMD
May 2021 - May 2021: From MOMENTUM trial for DMD
Checkmark Interim data from the MOMENTUM study
Dec 2020 - Dec 2020: Interim data from the MOMENTUM study
Checkmark Data from MOMENTUM trial for Duchenne muscular dystrophy
More
Active, not recruiting
2
62
Europe, Canada, US
Vesleteplirsen, SRP-5051
Sarepta Therapeutics, Inc.
Duchenne Muscular Dystrophy
10/23
01/29
PWS-001, NCT05879614: An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome

Withdrawn
2
20
US
NNZ-2591, Cyclo-L-Glycyl-L-2-Allylproline
Neuren Pharmaceuticals Limited
Prader-Willi Syndrome
06/25
06/25
NCT06332807: AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)

Recruiting
1/2
12
US
NGGT002
NGGT INC.
Phenylketonurias
12/30
12/30
DELIVER, NCT05524883 / 2021-005478-24: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Recruiting
1/2
88
Europe, Canada, US, RoW
DYNE-251, Placebo
Dyne Therapeutics, Dyne Therapeutics, Inc
Duchenne Muscular Dystrophy (DMD)
11/29
11/29
NCT05683379: AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Boys With DMD

Recruiting
N/A
200
US
AAV8 DetectCDx
REGENXBIO Inc.
Duchenne Muscular Dystrophy
12/24
12/24
Parker, John
NCT04967664 / 2021-001409-64: Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

Active, not recruiting
3
409
Europe, US
Qutenza (capsaicin) 8% topical system, capsaicin 0.04% topical system
Averitas Pharma, Inc., Averitas Pharma, Inc.
Post Surgical Neuropathic Pain
01/25
08/25
TRANSCEND-T2D-1, NCT06354660: Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Recruiting
3
480
US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Diabetes Type 2
06/26
07/26
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Recruiting
3
600
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
OSA, Overweight or Obesity
11/26
01/27
TRIUMPH-5, NCT06662383: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Recruiting
3
800
Europe, US, RoW
Retatrutide, LY3437943, Tirzepatide, LY3298176
Eli Lilly and Company
Obesity
04/27
04/27
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
NCT06037252: A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Recruiting
2
350
US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity
01/26
10/26
SECURE-T2D, NCT05815342: OP5-005 Using Omnipod 5 in Adults With Type 2

Completed
N/A
343
US
Omnipod 5 Automated Glucose Control System
Insulet Corporation, Jaeb Center for Health Research
Type2 Diabetes
03/24
03/24
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Recruiting
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
NCT02907398: Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry

Active, not recruiting
N/A
5000
Europe, US
Inspire therapy, ADHERE, No intervention, CONTROL
Inspire Medical Systems, Inc.
Obstructive Sleep Apnea
09/25
12/25
Brian, Susan R
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
ACHIEVE-5, NCT06109311: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

Recruiting
3
520
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
06/25
06/25
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Active, not recruiting
3
2300
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
04/26
05/26
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1040
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
06/26
09/26
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Recruiting
2
250
US, RoW
LY3841136, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
06/25
09/25
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Recruiting
2
275
US, RoW
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
NCT06124807: A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
179
US, RoW
LY3305677, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
01/25
05/25
COACH, NCT03340831: Continuous Monitoring and Control of Hypoglycemia

Recruiting
N/A
1388
US
Continuous Glucose Monitoring (CGM)
DexCom, Inc.
Diabetes
12/23
12/23
Lopez, Amy
NCT06366464: A Study of Pitolisant in Patients with Prader-Willi Syndrome

Recruiting
3
134
US
Pitolisant tablet, pitolisant, Placebo tablet, placebo
Harmony Biosciences, LLC
Prader-Willi Syndrome
07/26
07/27
Depression, NCT04489485: Online System for Identifying and Addressing Teen in Primary Care

Recruiting
N/A
580
US
Teen Depression Module used for care
Total Child Health, Inc., National Institute of Mental Health (NIMH), Foresight Logic
Major Depression, Dysthymia, Depressive Symptoms
06/23
06/23
GOETSCH, NICHOLAS
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Active, not recruiting
3
1667
Japan, US
Remternetug (IV), LY3372993, Remternetug (SC), Placebo
Eli Lilly and Company
Alzheimer's Disease
06/24
03/26
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Active, not recruiting
3
2196
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
PhD, Gregory E Cooper
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Active, not recruiting
3
2196
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
Luna, Eduardo Dusty
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor

Recruiting
3
1250
Canada, US, RoW
Retatrutide, LY3437943, Semaglutide
Eli Lilly and Company
Diabetes Mellitus, Type 2
12/26
03/27
NCT06297603: Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Recruiting
3
320
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes
09/26
10/26
TRANSCEND-T2D-1, NCT06354660: Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Recruiting
3
480
US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Diabetes Type 2
06/26
07/26
NCT06366464: A Study of Pitolisant in Patients with Prader-Willi Syndrome

Recruiting
3
134
US
Pitolisant tablet, pitolisant, Placebo tablet, placebo
Harmony Biosciences, LLC
Prader-Willi Syndrome
07/26
07/27
SURMOUNT-ADOLESCENTS-2, NCT06439277: A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities

Recruiting
3
300
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Weight Gain
05/27
06/27
QWINT-1, NCT05662332: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
795
US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, T2D
07/24
07/24
ACHIEVE-5, NCT06109311: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

Recruiting
3
520
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
06/25
06/25
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Active, not recruiting
3
2196
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1040
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
06/26
09/26
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Recruiting
2
275
US, RoW
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
Ahmad, Tanvir
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor

Recruiting
3
1250
Canada, US, RoW
Retatrutide, LY3437943, Semaglutide
Eli Lilly and Company
Diabetes Mellitus, Type 2
12/26
03/27
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
Conaway, Herbert C
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
Meyers, Julia
NCT06366464: A Study of Pitolisant in Patients with Prader-Willi Syndrome

Recruiting
3
134
US
Pitolisant tablet, pitolisant, Placebo tablet, placebo
Harmony Biosciences, LLC
Prader-Willi Syndrome
07/26
07/27

Download Options